Moderna Therapeutics’ $500 million equity financing round

Placement agents for this financing round were Goldman Sachs & Co. LLC, JP Morgan Securities LLC and Morgan Stanley & Co. LLC. Goodwin Procter provided legal counsel.

Moderna Therapeutics, a clinical stage biotechnology company that is pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for high unmet medical needs in patients, has raised $500 million in a new funding round. This latest equity financing includes support from new U.S. and international institutional investors, and existing institutional investors.

New investors include a wholly-owned subsidiary of the Abu Dhabi Investment Authority (ADIA), BB Biotech AG, Julius Baer, Singapore-based EDBI and Sequoia Capital China. Existing investors that also participated in this round include Fidelity Management & Research Company, Pictet, Viking Global Investors, ArrowMark Partners and Alexandria Venture Investments.

The Goodwin team was led by partners Stuart Cable (Picture), John Mutkoski, Kingsley Taft and associates Patricia Mets, Amoli Pandya and Sarah Smith.

Involved fees earner: Stuart Cable – Goodwin Procter; John Mutkoski – Goodwin Procter; Kingsley Taft – Goodwin Procter; Patricia Mets – Goodwin Procter; Amoli Pandya – Goodwin Procter; Sarah Smith – Goodwin Procter;

Law Firms: Goodwin Procter;

Clients: Moderna Therapeutics;


Author: Ambrogio Visconti